Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 6/20 | 0.66 |
| ▸ | IL23R | Q5VWK5 | 8/20 | 0.65 |
| ▸ | GLP1R | P43220 | 5/20 | 0.64 |
| ▸ | ECE1 | P42892 | 1/20 | 0.64 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29983249 | 0.97 | NR3C1 (0.69) | NR3C1IL23RGLP1RECE1MUS81 | |
| SCHEMBL29491080 | 0.89 | NR3C1 (0.76) | NR3C1IL23RGLP1RECE1MUS81 | |
| SCHEMBL29736869 | 0.88 | NR3C1 (0.72) | NR3C1IL23RGLP1RECE1MUS81 | |
| SCHEMBL31514295 | 0.88 | NPBWR1 (0.69) | NR3C1IL23RGLP1RECE1MUS81 | |
| Lycotoxin I SCHEMBL29412262 | 0.87 | GLP1R (0.66) | NR3C1GLP1RECE1MUS81 | |
| SCHEMBL30008855 | 0.87 | NR3C1 (0.70) | NR3C1IL23RGLP1RECE1MUS81 | |
| SCHEMBL29736864 | 0.86 | NR3C1 (0.72) | NR3C1IL23RGLP1RECE1MUS81 | |
| SCHEMBL30906493 | 0.86 | GLP1R (0.70) | IL23RGLP1RECE1MUS81 | |
| SCHEMBL31683311 | 0.86 | GLP1R (0.67) | NR3C1IL23RGLP1RECE1MUS81 | |
| SCHEMBL31140800 | 0.86 | GLP1R (0.70) | NR3C1GLP1RECE1MUS81 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 336 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025106551-A1 | HYDROGEL COMPOSITIONS COMPRISING SYNERGISTIC ANTIMICROBIAL PEPTIDES (AMPS) AND METHODS OF MAKING SAME | ROWAN UNIVERSITY (US) | 2025-05-22 | — | — | WO | claimed |
| CN-116376815-B | Culture medium for promoting osteoblast differentiation of mesenchymal stem cells | 山东科金生物发展有限公司 | 2024-05-31 | — | — | CN | claimed |
| CN-116376815-A | Culture medium for promoting osteoblast differentiation of mesenchymal stem cells | 山东科金生物发展有限公司 | 2023-07-04 | — | — | CN | claimed |
| EP-4077361-A1 | STRUCTURALLY-STABILIZED ONCOLYTIC PEPTIDES AND USES THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2022-10-26 | — | — | EP | claimed |
| EP-3129044-B1 | PEPTIDOGLYCAN HYDROLASE FOR USE IN THE TREATMENT OF CHRONIC BACTERIAL INFECTIONS | LYSANDO AG (LI) | 2022-09-07 | — | — | EP | claimed |
| US-20260131044-A1 | FIBERS ELECTROSPINNING INCLUDING MICROFLUIDICS METHOD | UNIV OF TARTU (EE) | 2026-05-14 | — | — | US | disclosed |
| US-20260132404-A1 | MODIFIED OLIGONUCLEOTIDES AND DOUBLE-STRANDED RNAS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4495237-B1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ARBUTUS BIOPHARMA CORP (CA) | 2026-05-13 | — | — | EP | disclosed |
| US-12622922-B2 | Compositions and methods for metal containing formulations capable of modulating immune response | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2026-05-12 | — | — | US | disclosed |
| US-12618096-B2 | Rapid screen for antibiotic resistance and treatment regimen | Secretary of State for Health and Social Care (GB) | 2026-05-05 | — | — | US | disclosed |
| EP-4729120-A2 | METHODS AND COMPOSITIONS FOR TREATING A BLEEDING EVENT IN A SUBJECT HAVING HEMOPHILIA | Genzyme Corporation (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12600965-B2 | Modified double stranded oligonucleotide | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-04-14 | — | — | US | disclosed |
| EP-3541406-B1 | NEW ANTIMICROBIAL AGENTS AGAINST STAPHYLOCOCCUS AUREUS | LYSANDO AG (LI) | 2022-03-16 | — | — | EP | disclosed |
| US-20220072023-A1 | COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-03-10 | — | — | US | disclosed |
| WO-2022051677-A1 | COMPOSITIONS AND METHODS FOR CAPPING RNAS | VERVE THERAPEUTICS, INC. (US) | 2022-03-10 | — | — | WO | disclosed |
| US-20220062373-A1 | Methods for Modulating Macrophage Activity | Riptide Bioscience, Inc. | 2022-03-03 | — | — | US | disclosed |
| US-20220064623-A1 | ENDOLYSIN VARIANT | SASINAPAS CO., LTD. (TH) | 2022-03-03 | — | — | US | disclosed |
| US-11261447-B2 | Methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-03-01 | — | — | US | disclosed |
| US-20220056444-A1 | PROCESS TO INHIBIT OR ELIMINATE EOSINOPHILIC DISEASES OF THE AIRWAY AND RELATED CONDITIONS | EMPIRICO INC. | 2022-02-24 | — | — | US | disclosed |
| EP-3941508-A1 | NON-HYDROLYZABLE, NON-CLEAVABLE, STABLE LINKERS FOR PRECISION THERAPEUTICS AND USES THEREOF | The Trustees of Columbia University in the City of New York (US) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12600965-B2 | Modified double stranded oligonucleotide | NSUN2, EIF2AK2, ADAR | NR3C1 3277/4885IL23R 2003/4885GLP1R 975/4885 |
| US-20220072023-A1 | COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE | MYD88, STING1, TLR3 | NR3C1 1201/4885IL23R 809/4885GLP1R 3386/4885 |
| US-20260132404-A1 | MODIFIED OLIGONUCLEOTIDES AND DOUBLE-STRANDED RNAS | RNASEL, NSUN2, ADAR | NR3C1 4023/4885IL23R 3323/4885GLP1R 1422/4885 |
| US-20220062373-A1 | Methods for Modulating Macrophage Activity | CD209, CD68, CD14 | NR3C1 1644/4885IL23R 607/4885GLP1R 782/4885 |
| US-12618096-B2 | Rapid screen for antibiotic resistance and treatment regimen | MYD88, SLC11A2, STAT1 | NR3C1 4548/4885IL23R 1323/4885GLP1R 178/4885 |
| US-11261447-B2 | Methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression | HAO1, HAO2, HAAO | NR3C1 2730/4885IL23R 4447/4885GLP1R 4586/4885 |
| US-12622922-B2 | Compositions and methods for metal containing formulations capable of modulating immune response | STING1, CGAS, TLR3 | NR3C1 2559/4885IL23R 1055/4885GLP1R 1312/4885 |
| US-20260131044-A1 | FIBERS ELECTROSPINNING INCLUDING MICROFLUIDICS METHOD | CUTA, TNF, IL33 | NR3C1 4064/4885IL23R 3791/4885GLP1R 1845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.